Florestan Koll

463 total citations
38 papers, 214 citations indexed

About

Florestan Koll is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Florestan Koll has authored 38 papers receiving a total of 214 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Surgery, 20 papers in Pulmonary and Respiratory Medicine and 12 papers in Oncology. Recurrent topics in Florestan Koll's work include Bladder and Urothelial Cancer Treatments (21 papers), Urinary and Genital Oncology Studies (15 papers) and Prostate Cancer Treatment and Research (14 papers). Florestan Koll is often cited by papers focused on Bladder and Urothelial Cancer Treatments (21 papers), Urinary and Genital Oncology Studies (15 papers) and Prostate Cancer Treatment and Research (14 papers). Florestan Koll collaborates with scholars based in Germany, Türkiye and Canada. Florestan Koll's co-authors include Felix K.‐H. Chun, Séverine Banek, Jürgen E. Gschwend, Jens Köllermann, Peter J. Wild, Benedikt Hoeh, Henning Reis, Mike Wenzel, Sebastian C. Schmid and Luis Kluth and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and International Journal of Molecular Sciences.

In The Last Decade

Florestan Koll

34 papers receiving 214 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Florestan Koll Germany 9 97 87 80 44 32 38 214
David Morris United States 8 65 0.7× 102 1.2× 68 0.8× 64 1.5× 9 0.3× 25 224
Atsushi Komaru Japan 11 44 0.5× 133 1.5× 114 1.4× 52 1.2× 22 0.7× 27 264
Seiji Yunotani Japan 8 146 1.5× 94 1.1× 127 1.6× 82 1.9× 11 0.3× 21 296
Anishka D'souza United States 6 57 0.6× 95 1.1× 87 1.1× 66 1.5× 8 0.3× 25 201
Elwira Bakuła‐Zalewska Poland 11 75 0.8× 37 0.4× 44 0.6× 114 2.6× 18 0.6× 25 297
Touraj Taheri Australia 8 58 0.6× 40 0.5× 72 0.9× 86 2.0× 9 0.3× 20 213
Jordan Kardos United States 7 129 1.3× 78 0.9× 80 1.0× 111 2.5× 4 0.1× 11 254
Brigitte C.M. Haberkorn Netherlands 11 49 0.5× 106 1.2× 191 2.4× 29 0.7× 36 1.1× 19 248
M. Pulido France 6 31 0.3× 118 1.4× 131 1.6× 47 1.1× 4 0.1× 16 241

Countries citing papers authored by Florestan Koll

Since Specialization
Citations

This map shows the geographic impact of Florestan Koll's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Florestan Koll with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Florestan Koll more than expected).

Fields of papers citing papers by Florestan Koll

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Florestan Koll. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Florestan Koll. The network helps show where Florestan Koll may publish in the future.

Co-authorship network of co-authors of Florestan Koll

This figure shows the co-authorship network connecting the top 25 collaborators of Florestan Koll. A scholar is included among the top collaborators of Florestan Koll based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Florestan Koll. Florestan Koll is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wenzel, Mike, Benedikt Hoeh, Carolin Siech, et al.. (2025). Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy. European Journal of Nuclear Medicine and Molecular Imaging. 52(6). 2015–2022. 1 indexed citations
2.
Wenzel, Mike, Benedikt Hoeh, Florestan Koll, et al.. (2024). Influence of Tumor Characteristics and Time to Metastatic Disease on Oncological Outcomes in Metachronous Metastatic Prostate Cancer Patients. Clinical Genitourinary Cancer. 22(5). 102158–102158. 2 indexed citations
3.
Tallman, Jacob E., Florestan Koll, Sizhi Paul Gao, et al.. (2024). Abstract A029: Transcriptome analysis of variant histology bladder cancer reveals drug target heterogeneity. Clinical Cancer Research. 30(10_Supplement). A029–A029. 1 indexed citations
4.
Gao, Sizhi Paul, Fengshen Kuo, Florestan Koll, et al.. (2024). Abstract 4632: Lineage plasticity as a determinant of antibody-drug conjugate target expression in urothelial bladder cancer. Cancer Research. 84(6_Supplement). 4632–4632. 3 indexed citations
5.
Siech, Carolin, Mike Wenzel, Cristina Cano Garcia, et al.. (2024). The Association Between Lymphovascular or Perineural Invasion in Radical Prostatectomy Specimen and Biochemical Recurrence. Cancers. 16(21). 3648–3648. 1 indexed citations
6.
Wenzel, Mike, Florestan Koll, Benedikt Hoeh, et al.. (2024). Real-World Comparison of Cabazitaxel Versus177Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine. 66(1). 61–66. 3 indexed citations
7.
Stratmann, Jan, Florestan Koll, Sebastian Wagner, et al.. (2024). Concepts of lines of therapy in cancer treatment: findings from an expert interview-based study. BMC Research Notes. 17(1). 137–137.
8.
Wenzel, Mike, Benedikt Hoeh, Florestan Koll, et al.. (2024). Impact of homologous recombination repair/BReast CAncer ( BRCA ) gene alterations on survival in a real‐world setting of metastatic prostate cancer. British Journal of Urology. 135(1). 117–124. 5 indexed citations
9.
Koll, Florestan, Markus Eckstein, Henning Reis, et al.. (2024). Histomolekulare Klassifikation des Urothelkarzinoms der Harnblase. PubMed. 45(2). 106–114.
10.
11.
Koll, Florestan, Séverine Banek, Luis Kluth, et al.. (2023). Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis. Journal of Translational Medicine. 21(1). 124–124. 25 indexed citations
12.
Banek, Séverine, Benedikt Hoeh, Cristina Cano Garcia, et al.. (2023). Metastatic Squamous Cell Carcinoma of the Urinary Bladder: Urgent Call for New Therapies. Urologia Internationalis. 108(1). 1–8. 8 indexed citations
13.
Wagner, Tobias, Florian Kirchhoff, Charlotte Düwel, et al.. (2023). Does experience change the role of systematic biopsy during MRI-fusion biopsy of the prostate?. World Journal of Urology. 41(10). 2699–2705. 3 indexed citations
14.
Koll, Florestan, et al.. (2022). Combination of radiation and immunotherapy in the treatment of genitourinary malignancies: A systematic review and meta-analysis. Urologic Oncology Seminars and Original Investigations. 41(5). 219–232. 2 indexed citations
15.
16.
Koll, Florestan, Bernhard Haller, Florian Kirchhoff, et al.. (2021). Evaluation of Pre-operative Biopsy, Surgical Procedures and Oncologic Outcomes in Upper Tract Urothelial Carcinoma (UTUC). Frontiers in Surgery. 8. 790738–790738. 6 indexed citations
17.
18.
Retz, Margitta, et al.. (2020). Clinical Practice Guidelines for Bladder Cancer: A Systematic Review and Meta-Analysis Using the AGREE II Instrument. Urologia Internationalis. 105(1-2). 31–40. 9 indexed citations
19.
Lunger, Lukas, Margitta Retz, Gregor Weirich, et al.. (2020). KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy. Prostate Cancer and Prostatic Diseases. 24(2). 362–369. 8 indexed citations
20.
Koll, Florestan, Klaus Mantwill, Klaus‐Peter Janssen, et al.. (2018). The Oncolytic Adenovirus XVir-N-31 as a Novel Therapy in Muscle-Invasive Bladder Cancer. Human Gene Therapy. 30(1). 44–56. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David Morris Breakdown of academic impact, for papers by Atsushi Komaru Breakdown of academic impact, for papers by Seiji Yunotani Breakdown of academic impact, for papers by Anishka D'souza Breakdown of academic impact, for papers by Elwira Bakuła‐Zalewska Breakdown of academic impact, for papers by Touraj Taheri Breakdown of academic impact, for papers by Jordan Kardos Breakdown of academic impact, for papers by Brigitte C.M. Haberkorn Breakdown of academic impact, for papers by M. Pulido
Rankless by CCL
2026